SG11201708153XA - Treatment of lung cancer with inhibitors of glutaminase - Google Patents
Treatment of lung cancer with inhibitors of glutaminaseInfo
- Publication number
- SG11201708153XA SG11201708153XA SG11201708153XA SG11201708153XA SG11201708153XA SG 11201708153X A SG11201708153X A SG 11201708153XA SG 11201708153X A SG11201708153X A SG 11201708153XA SG 11201708153X A SG11201708153X A SG 11201708153XA SG 11201708153X A SG11201708153X A SG 11201708153XA
- Authority
- SG
- Singapore
- Prior art keywords
- glutaminase
- inhibitors
- treatment
- lung cancer
- lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143494P | 2015-04-06 | 2015-04-06 | |
| US201562149489P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/026127 WO2016164401A1 (en) | 2015-04-06 | 2016-04-06 | Treatment of lung cancer with inhibitors of glutaminase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708153XA true SG11201708153XA (en) | 2017-11-29 |
Family
ID=57015711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708153XA SG11201708153XA (en) | 2015-04-06 | 2016-04-06 | Treatment of lung cancer with inhibitors of glutaminase |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10441587B2 (en) |
| EP (1) | EP3280415A4 (en) |
| JP (2) | JP6944377B2 (en) |
| KR (1) | KR20170132333A (en) |
| CN (1) | CN107949387B (en) |
| AU (1) | AU2016246521B2 (en) |
| BR (1) | BR112017021312A2 (en) |
| CA (1) | CA2981762A1 (en) |
| EA (1) | EA035354B1 (en) |
| HK (1) | HK1254349A1 (en) |
| IL (1) | IL254876A0 (en) |
| MX (1) | MX2017012824A (en) |
| SG (1) | SG11201708153XA (en) |
| WO (1) | WO2016164401A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| PT2920168T (en) | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Heterocyclic glutaminase inhibitors |
| BR112016024513A2 (en) | 2014-04-30 | 2017-08-15 | Pfizer | cycloalkyl-linked diheterocycle derivatives |
| AU2015300825B2 (en) | 2014-08-07 | 2019-10-10 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| CN108601767A (en) | 2015-10-05 | 2018-09-28 | 卡利泰拉生物科技公司 | With the combination treatment of glutamine enzyme inhibitor and immune oncology medicament |
| EP3503893A4 (en) * | 2016-08-25 | 2020-04-29 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| AU2018231058A1 (en) * | 2017-03-10 | 2019-09-19 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| JP7188936B2 (en) * | 2018-08-21 | 2022-12-13 | 国立大学法人富山大学 | anti-inflammatory agent |
| JP7156856B2 (en) * | 2018-08-21 | 2022-10-19 | 国立大学法人富山大学 | anti-obesity agent |
| WO2021076814A1 (en) * | 2019-10-15 | 2021-04-22 | Cornell University | Methods of inhibiting liver-type glutaminase, gls2 |
| CN111514460B (en) * | 2020-05-22 | 2021-12-14 | 西安交通大学 | Application of atmospheric pressure cold plasma in inhibiting activity of glutaminase and enzyme inhibitor |
| CN113956233B (en) * | 2021-10-22 | 2023-06-06 | 南方医科大学 | Amide compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
| WO2023212718A2 (en) * | 2022-04-29 | 2023-11-02 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| ES2367311T3 (en) | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | MAP-2 PROTEOLYTIC DEGRADATION PRODUCTS AS DIAGNOSTIC BIOMARCATORS FOR NEURAL INJURIES. |
| EP2255818B1 (en) | 2008-02-19 | 2018-08-22 | Earnest Medicine Co., Ltd. | Oral or enteral composition useful for recovery of physical functions |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| CN103030597B (en) * | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor |
| US8604016B2 (en) * | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| EP2782570B1 (en) * | 2011-11-21 | 2019-09-18 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US10138479B2 (en) * | 2012-05-24 | 2018-11-27 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| KR20150054962A (en) | 2012-09-10 | 2015-05-20 | 셀진 코포레이션 | Methods for the treatment of locally advanced breast cancer |
| ES2690829T3 (en) | 2012-09-17 | 2018-11-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for the selection of patients who respond to treatment |
| PT2920168T (en) | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | Heterocyclic glutaminase inhibitors |
| WO2014081925A1 (en) | 2012-11-21 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| KR20150091389A (en) | 2012-12-03 | 2015-08-10 | 칼리테라 바이오사이언시즈 인코포레이티드 | Treatment of cancer with heterocyclic inhibitors of glutaminase |
| WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
| WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
| WO2015192014A1 (en) * | 2014-06-13 | 2015-12-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| WO2016004418A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| AU2015300825B2 (en) | 2014-08-07 | 2019-10-10 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
| WO2016077632A2 (en) | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| WO2016160980A1 (en) * | 2015-03-30 | 2016-10-06 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
| SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| US20180055825A1 (en) | 2016-08-25 | 2018-03-01 | Yu Liang | Treatment of cancer with inhibitors of glutaminase |
| EP3503893A4 (en) | 2016-08-25 | 2020-04-29 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
-
2016
- 2016-04-06 SG SG11201708153XA patent/SG11201708153XA/en unknown
- 2016-04-06 BR BR112017021312A patent/BR112017021312A2/en not_active IP Right Cessation
- 2016-04-06 EA EA201792227A patent/EA035354B1/en not_active IP Right Cessation
- 2016-04-06 EP EP16777159.1A patent/EP3280415A4/en not_active Withdrawn
- 2016-04-06 WO PCT/US2016/026127 patent/WO2016164401A1/en active Application Filing
- 2016-04-06 MX MX2017012824A patent/MX2017012824A/en unknown
- 2016-04-06 JP JP2017552153A patent/JP6944377B2/en active Active
- 2016-04-06 AU AU2016246521A patent/AU2016246521B2/en not_active Ceased
- 2016-04-06 KR KR1020177032006A patent/KR20170132333A/en not_active Application Discontinuation
- 2016-04-06 CN CN201680032522.7A patent/CN107949387B/en not_active Expired - Fee Related
- 2016-04-06 US US15/091,816 patent/US10441587B2/en not_active Expired - Fee Related
- 2016-04-06 CA CA2981762A patent/CA2981762A1/en not_active Abandoned
-
2017
- 2017-10-03 IL IL254876A patent/IL254876A0/en unknown
-
2018
- 2018-10-19 HK HK18113425.8A patent/HK1254349A1/en unknown
-
2021
- 2021-04-16 JP JP2021069815A patent/JP2021102662A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107949387B (en) | 2021-08-13 |
| CA2981762A1 (en) | 2016-10-13 |
| JP2018510884A (en) | 2018-04-19 |
| IL254876A0 (en) | 2017-12-31 |
| WO2016164401A1 (en) | 2016-10-13 |
| US10441587B2 (en) | 2019-10-15 |
| HK1254349A1 (en) | 2019-07-19 |
| KR20170132333A (en) | 2017-12-01 |
| EA201792227A1 (en) | 2018-11-30 |
| JP6944377B2 (en) | 2021-10-06 |
| US20160287585A1 (en) | 2016-10-06 |
| AU2016246521A8 (en) | 2019-08-15 |
| WO2016164401A8 (en) | 2017-11-23 |
| EA035354B1 (en) | 2020-06-01 |
| EP3280415A1 (en) | 2018-02-14 |
| AU2016246521A1 (en) | 2017-11-02 |
| BR112017021312A2 (en) | 2018-06-26 |
| MX2017012824A (en) | 2018-05-15 |
| JP2021102662A (en) | 2021-07-15 |
| AU2016246521B2 (en) | 2020-07-09 |
| CN107949387A (en) | 2018-04-20 |
| EP3280415A4 (en) | 2018-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254349A1 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| IL259783A (en) | Methods of treatment of malignancies | |
| HK1251408A1 (en) | Methods of treating cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL249476A0 (en) | Combination therapy with glutaminase inhibitors | |
| HK1254129A1 (en) | Methods of administering glutaminase inhibitors | |
| IL261959B1 (en) | Treatment of cancer with tg02 | |
| HK1254882A1 (en) | Combination therapies for treatment of cancer | |
| HUE053744T2 (en) | Combination treatment of cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| SG11201605745VA (en) | Targeting clptm1l for treatment and prevention of cancer | |
| GB201408297D0 (en) | Treatment of cancer | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201407837D0 (en) | Methods of cancer therapy | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201512723D0 (en) | Treatment of cancer | |
| GB201507928D0 (en) | Treatment of cancer | |
| GB201504617D0 (en) | Treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer | |
| GB201405075D0 (en) | Treatment of cancer |